ECSP088096A - Derivados de 2-oxo-imidazol sustituidos con dihidroxialquilo en n - Google Patents

Derivados de 2-oxo-imidazol sustituidos con dihidroxialquilo en n

Info

Publication number
ECSP088096A
ECSP088096A EC2008008096A ECSP088096A ECSP088096A EC SP088096 A ECSP088096 A EC SP088096A EC 2008008096 A EC2008008096 A EC 2008008096A EC SP088096 A ECSP088096 A EC SP088096A EC SP088096 A ECSP088096 A EC SP088096A
Authority
EC
Ecuador
Prior art keywords
agents
prophylaxis
treatment
remedy
useful
Prior art date
Application number
EC2008008096A
Other languages
English (en)
Inventor
Masaya Hashimoto
Yoshikazu Iwasawa
Hiroshi Kawamoto
Hisashi Ohta
Satoshi Ozaki
Takeshi Sagara
Hiroki Sakoh
Atsushi Satoh
Original Assignee
Banyu Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banyu Pharma Co Ltd filed Critical Banyu Pharma Co Ltd
Publication of ECSP088096A publication Critical patent/ECSP088096A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

[Objeto] Proporcionar derivados de 2-oxoimidazol sustituidos con dihidroxialquilo en N que son útiles como medicinas. [Medios de solución] La invención proporciona los compuestos representados por la fórmula (I) [en los que, R representa un grupo alquilo C1 - C6 sustituido con dihidroxi, y Cy representa un grupo carbocíclico alifático bicíclico o tricíclico C6-C10 opcionalmente sustituido]. Estos compuestos actúan como antagonistas del receptor de nociceptina, y son útiles, por ejemplo, como agentes para aliviar la tolerancia a analgésicos narcóticos, dependencia o adicción a analgésicos narcóticos; potenciadores de la analgesia; agentes contra la obesidad o supresores del apetito; agentes de tratamiento o profilaxis para deficiencia cognitiva y demencia/ amnesia; agentes para tratar anormalidad cognitiva del desarrollo; remedio para la esquizofrenia; agentes para tratar enfermedades neurodegenerativas; antidepresivos o agentes de tratamiento para trastorno afectivo; agentes de tratamiento o profilaxis para diabetes insípida; agentes de tratamiento o profilaxis para poliuria; y remedio para la hipotensión y similares.
EC2008008096A 2005-07-13 2008-01-10 Derivados de 2-oxo-imidazol sustituidos con dihidroxialquilo en n ECSP088096A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005204264 2005-07-13

Publications (1)

Publication Number Publication Date
ECSP088096A true ECSP088096A (es) 2008-02-20

Family

ID=37637260

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008096A ECSP088096A (es) 2005-07-13 2008-01-10 Derivados de 2-oxo-imidazol sustituidos con dihidroxialquilo en n

Country Status (23)

Country Link
EP (1) EP1914232B1 (es)
JP (1) JP4748162B2 (es)
KR (1) KR20080033262A (es)
CN (1) CN101223158B (es)
AR (1) AR054816A1 (es)
AU (1) AU2006267391B2 (es)
BR (1) BRPI0613109A2 (es)
CA (1) CA2614688A1 (es)
CR (1) CR9692A (es)
DE (1) DE602006018950D1 (es)
DO (1) DOP2006000165A (es)
EC (1) ECSP088096A (es)
ES (1) ES2355580T3 (es)
IL (1) IL188418A0 (es)
MA (1) MA29738B1 (es)
NI (1) NI200800003A (es)
NO (1) NO20080770L (es)
NZ (1) NZ565026A (es)
PE (1) PE20070176A1 (es)
RU (1) RU2414456C2 (es)
TW (1) TW200740436A (es)
WO (1) WO2007007890A1 (es)
ZA (1) ZA200711025B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009033757A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
US20100184673A1 (en) * 2007-09-11 2010-07-22 Dorian Bevec Use of parathyroid hormone ( 1-34 ) as anti-hiv agent
RU2582339C2 (ru) * 2010-05-27 2016-04-27 Таргасепт, Инк. Неконкурентные антагонисты никотиновых рецепторов
PL3345907T3 (pl) * 2015-09-01 2020-09-07 Taiho Pharmaceutical Co., Ltd. Związki pirazolo[3,4-d]pirymidynowe lub ich sole
KR20240022630A (ko) * 2021-07-14 2024-02-20 이창 휴먼웰 파마슈티칼 코포레이션, 리미티드 피페리딘 유도체 및 그 약물 조성물, 제조 방법과 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2200468A1 (en) * 1994-10-27 1996-05-09 Wayne J. Thompson Muscarine antagonists
EP0898568B1 (en) * 1996-04-19 2006-10-04 Neurosearch A/S 1-(4-piperidyl)-benzimidazoles having neurotrophic activity
ATE276242T1 (de) * 1997-05-30 2004-10-15 Banyu Pharma Co Ltd 2-oxoimidazol-derivate
DK1049689T3 (da) * 1998-01-19 2002-07-22 Pfizer 4-(2-keto-1-benzimidazolinyl)piperidinderivater som ORL1-receptoragonister
JP2003524634A (ja) * 1999-12-06 2003-08-19 ユーロ−セルティーク，エス．エイ． ノシセプチン受容体親和性を有するベンズイミダゾール化合物

Also Published As

Publication number Publication date
ZA200711025B (en) 2008-12-31
AR054816A1 (es) 2007-07-18
CN101223158A (zh) 2008-07-16
AU2006267391A1 (en) 2007-01-18
TW200740436A (en) 2007-11-01
EP1914232B1 (en) 2010-12-15
ES2355580T3 (es) 2011-03-29
AU2006267391B2 (en) 2011-12-08
PE20070176A1 (es) 2007-03-09
NI200800003A (es) 2008-07-21
NO20080770L (no) 2008-04-11
CR9692A (es) 2008-02-21
KR20080033262A (ko) 2008-04-16
DOP2006000165A (es) 2007-02-28
CA2614688A1 (en) 2007-01-18
IL188418A0 (en) 2008-11-03
RU2414456C2 (ru) 2011-03-20
EP1914232A1 (en) 2008-04-23
WO2007007890A1 (ja) 2007-01-18
EP1914232A4 (en) 2009-10-28
RU2008105396A (ru) 2009-08-20
NZ565026A (en) 2010-09-30
DE602006018950D1 (de) 2011-01-27
JPWO2007007890A1 (ja) 2009-01-29
BRPI0613109A2 (pt) 2012-12-04
JP4748162B2 (ja) 2011-08-17
MA29738B1 (fr) 2008-09-01
CN101223158B (zh) 2013-01-09

Similar Documents

Publication Publication Date Title
ECSP088096A (es) Derivados de 2-oxo-imidazol sustituidos con dihidroxialquilo en n
ECSP055536A (es) Derivados de 1-heterociclilalquil-3-sulfonilindol o indazol como ligandos de 5-hidroxitriptamina-6
CY1115337T1 (el) Παραγωγα ν-οξειδιου και/ή di-n- οξειδιου των σταθεροποιητων/παραγοντων τροποποιησης ληπτη ντοπαμινης (dopamine) που εμφανιζουν βελτιωμενα προφιλ καρδιαγγειακων παρενεργειων
GT200800033A (es) Antagonistas de los receptores 2 de dopamina de rapida disociacion
CO6300941A2 (es) Compuestos de quinuclidina como ligandos del receptor nicotinico de acetilcolina alfa 7
TW200800958A (en) N-substituted-azacyclylamines as histamine-3 antagonists
GT201500092A (es) Moduladores de quinolinillo unidos a fenilo de ror-gamma-t
PA8795601A1 (es) Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de histamina-3
CR7643A (es) Derivados de 1-heterociclialquil -3-sulfonilazaindol o azaindazol como ligandos de 5-hidroxitriptamina-6
CY1112604T1 (el) Χρηση ενος βητα αποκλειστη για την παρασκευη ενος φαρμακου για τη θεραπεια αιμαγγειωματων
CL2011001923A1 (es) Compuestos agonistas y antagonistas del receptor s1p5; y uso de los compuestos en la preparacion de medicamentos útiles para el tratamiento de enfermedades mediadas por el refceptor s1p, tales como enfermedades neurodedenerativas.
PA8795701A1 (es) Derivados de isoquinolinilo e isoindolinilo como antagonistas de histamina-3
CR20150057A (es) Antagonistas del receptor de 5-ht3
PA8768901A1 (es) Antagonistas del receptor de dopamina 2 de rápida disociación
UY29197A1 (es) Compuestos de n-sulfonilaminobencil-2-fenoxiacetamida sustituidos
NI201100117A (es) Antagonistas de 4 -- azetidinil - 1 - heteroaril - ciclohexanol del ccr2.
CR11500A (es) Derivados ciclopropilamina
MA32943B1 (fr) Piperidine spiro pyrrolidione et piperidinone substituees, leur preparation et leur utilisation therapeutique
UY31527A1 (es) Derivados ciclopropilamina
PA8790101A1 (es) Derivados de aminoalquilazol como antagonistas de histamina-3
MX2009012734A (es) Derivados de azaciclilbenzamida como antagonistas de histamina-3.
ECSP088176A (es) Derivados de azinil-3-sulfonilindazol como ligandos de5-hidroxitriptamina-6
CR9734A (es) Derivados de 3-sulfonilindazol sustituido como ligandos de 5-hidroxitriptamina-6
UY31646A1 (es) Uso de fenilimidazolidinas sustituidas para producir medicamentos para el tratamiento del síndrome metabólico
DE602005026965D1 (de) Zur behandlung von auf die modulation des dopamin-d3-rezeptors ansprechenden erkrankungen geeignete aminomethylsubstituierte bicyclische aromatische verbindungen